Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how ...

BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ETCompany ParticipantsJeff Stewart - EVP and Chief ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

AbbVie Inc. closed 15.13% below its 52-week high of $218.66, which the company reached on March 10th.

Small interfering RNA (siRNA) gained another vote of confidence, albeit back end-loaded, from big pharma as privately held ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy, some investors ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

The U.S. FDA granted Abbvie Inc. accelerated approval for antibody-drug conjugate (ADC) Teliso-V (telisotuzumab vedotin), newly branded Emrelis, making it the first treatment for previously treated ...